OncoSec Reports Positive Results from Phase II Trial of ImmunoPulse IL-12 in MCC

By: via Benzinga
OncoSec Medical Incorporated (NASDAQ: ONCS) today announced results from a Phase II trial demonstrating that its investigational ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.